Living Cell Technologies Ltd. (AU:1AI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Algorae Pharmaceuticals has expanded its therapeutic pipeline with 24 new AI-generated drug targets for preclinical evaluation, focusing on oncology indications with unmet needs. This development, facilitated by their proprietary AlgoraeOS platform, underscores the company’s competitive edge in AI-driven drug discovery. Successful preclinical outcomes may lead to further development, potentially in collaboration with other pharmaceutical firms.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.